An Open-Label, Single-Arm, Dose-Exploration Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of CT048 in Subjects With Advanced Solid Tumors
Latest Information Update: 02 Jun 2023
At a glance
- Drugs KJ-C1807 (Primary)
- Indications Adenocarcinoma; Digestive system neoplasms; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 30 May 2023 Status changed from not yet recruiting to recruiting.
- 02 Jun 2022 New trial record